STOCK TITAN

Liminal BioSciences Inc. - LMNL STOCK NEWS

Welcome to our dedicated page for Liminal BioSciences news (Ticker: LMNL), a resource for investors and traders seeking the latest updates and insights on Liminal BioSciences stock.

Liminal BioSciences Inc. (NASDAQ: LMNL) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for diseases with unmet medical needs. Established originally as Prometic Life Sciences Inc., the company rebranded to its current name in October 2019 to better reflect its evolving mission.

The company operates through two core segments: Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment is spearheaded by its lead product candidate, Fezagepras (PBI-4050), aimed at treating idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. In parallel, the Plasma Derived Therapeutics segment focuses on plasma protein purification technologies, particularly for extracting therapeutic proteins from human plasma. One of its notable developments is Ryplazim, designed for treating congenital plasminogen deficiency.

Liminal BioSciences has a geographically diverse operational footprint with active business operations in Canada, the United Kingdom, and the United States. Reflecting its commitment to cutting-edge research, the company has a deep pipeline of projects including LMNL6511, LMNL6326, and GPR40 agonists, each targeting various metabolic, inflammatory, and fibrotic diseases.

Financially, Liminal BioSciences recently announced a definitive arrangement agreement with Structured Alpha LP (SALP) under which SALP will acquire all outstanding common shares of the company at a significant premium, solidifying investor confidence in the company's strategic direction. The transaction is expected to close by the end of September 2023, pending necessary approvals and conditions.

Overall, Liminal BioSciences stands at the forefront of biopharmaceutical innovation, driven by its integrated drug discovery platform, medicinal chemistry expertise, and a robust understanding of GPCR biology. The company's collaborations and partnerships further reinforce its potential to deliver transformative healthcare solutions to patients worldwide.

Rhea-AI Summary
Liminal BioSciences Inc. has completed a transaction with Structured Alpha LP, where SALP acquired all outstanding common shares of Liminal BioSciences at a price of US$8.50 per share. As a result, the shares will no longer be listed on the Nasdaq Capital Market, and Liminal BioSciences will cease to be a reporting issuer under Canadian securities law. The company is focused on developing small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Liminal BioSciences received final court order for plan of arrangement with Structured Alpha LP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Liminal BioSciences shareholders approve plan of arrangement with Structured Alpha LP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Summary
Liminal BioSciences files amended Schedule 13E-3 and supplement to the management information circular
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Liminal BioSciences Inc. has obtained an interim order from the Ontario Superior Court of Justice for a proposed arrangement with Structured Alpha LP. Under the arrangement, SALP will acquire all outstanding common shares of Liminal BioSciences not currently owned by SALP or its affiliates at a price of US$8.50 per share. The arrangement is subject to shareholder approval and the issuance of a final court order.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary
Liminal BioSciences Inc. (Nasdaq: LMNL) provided an R&D update on their GPCR-targeted pipeline, including the nomination of a lead candidate for the OXER1 antagonist program. They also reported their financial results for the second quarter ended June 30, 2023, with a net loss from continuing operations of CAD 9 million. The company closed June 30, 2023, with over CAD 19 million cash on hand, expecting to provide cash runway into December 2023. Additionally, they entered into an Arrangement Agreement with Structured Alpha LP, potentially providing minority shareholders US$8.50 in cash per Common Share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
Rhea-AI Summary
Liminal BioSciences Inc. and Structured Alpha LP have entered into an agreement under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences. Liminal BioSciences shareholders will receive US$8.50 in cash per share, representing a premium of approximately 135% over the closing share price on Nasdaq on April 4, 2023. The transaction is expected to close no later than September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags

FAQ

What is the market cap of Liminal BioSciences (LMNL)?

The market cap of Liminal BioSciences (LMNL) is approximately 27.6M.

What does Liminal BioSciences Inc. specialize in?

Liminal BioSciences specializes in the discovery, development, and commercialization of novel treatments for diseases with unmet medical needs, focusing on small molecule therapeutics and plasma-derived therapeutics.

What is the lead product candidate of Liminal BioSciences?

The lead product candidate is Fezagepras (PBI-4050), which is aimed at treating idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome.

In which regions does Liminal BioSciences operate?

Liminal BioSciences operates in Canada, the United Kingdom, and the United States.

What recent significant transaction has Liminal BioSciences engaged in?

Liminal BioSciences has entered into a definitive arrangement agreement with Structured Alpha LP (SALP) to acquire all outstanding common shares at a substantial premium. This transaction is anticipated to close by the end of September 2023.

What is Ryplazim and what does it treat?

Ryplazim is a plasma protein purification product developed by Liminal BioSciences for the treatment of congenital plasminogen deficiency.

How does Liminal BioSciences contribute to the biopharmaceutical field?

Liminal BioSciences contributes through its integrated drug discovery platform, medicinal chemistry expertise, and deep understanding of GPCR biology to create potential best-in-class therapeutics for metabolic, inflammatory, and fibrotic diseases.

What are some products in Liminal BioSciences' pipeline?

The company's pipeline includes LMNL6511, LMNL6326, and GPR40 agonists, which target various metabolic, inflammatory, and fibrotic diseases.

What is the significance of the recent agreement with SALP for Liminal BioSciences?

The agreement with SALP, involving the acquisition of all outstanding shares, underscores investor confidence and provides Liminal BioSciences with significant financial backing to continue its innovative research and development efforts.

What was the former name of Liminal BioSciences Inc.?

The company was formerly known as Prometic Life Sciences Inc. before rebranding in October 2019.

Are there any ongoing clinical trials for Liminal BioSciences' products?

Yes, the selective antagonist LMNL6511 for the GPR84 receptor is expected to commence a Phase 1 clinical trial in the second half of 2023.

Liminal BioSciences Inc.

Nasdaq:LMNL

LMNL Rankings

LMNL Stock Data

27.62M
1.26M
61.26%
0.77%
0.02%
Biotechnology
Healthcare
Link
Canada
Laval